Zafgen, Inc. (ZFGN) Downgraded to Strong Sell at ValuEngine

ValuEngine lowered shares of Zafgen, Inc. (NASDAQ:ZFGN) from a sell rating to a strong sell rating in a research note released on Tuesday.

Separately, Zacks Investment Research upgraded shares of Zafgen from a hold rating to a buy rating and set a $4.00 price objective for the company in a research report on Saturday, July 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $6.38.

Zafgen (NASDAQ:ZFGN) opened at 3.51 on Tuesday. Zafgen has a 52 week low of $2.89 and a 52 week high of $5.46. The company has a 50 day moving average price of $3.46 and a 200 day moving average price of $3.87. The stock’s market cap is $96.47 million.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.03. During the same quarter last year, the company posted ($0.55) earnings per share. Analysts expect that Zafgen will post ($2.23) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Zafgen, Inc. (ZFGN) Downgraded to Strong Sell at ValuEngine” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2017/10/11/zafgen-inc-zfgn-downgraded-to-strong-sell-at-valuengine.html.

A number of institutional investors have recently modified their holdings of ZFGN. Wells Fargo & Company MN increased its holdings in Zafgen by 1,290.3% in the first quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 40,400 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Zafgen by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 104,199 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 5,794 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in Zafgen by 55.8% in the first quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 10,327 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Zafgen by 937.6% in the first quarter. JPMorgan Chase & Co. now owns 495,743 shares of the biopharmaceutical company’s stock valued at $2,311,000 after buying an additional 447,964 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its holdings in Zafgen by 40.9% in the first quarter. TIAA CREF Investment Management LLC now owns 169,836 shares of the biopharmaceutical company’s stock valued at $791,000 after buying an additional 49,308 shares in the last quarter. 48.52% of the stock is owned by institutional investors.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

What are top analysts saying about Zafgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zafgen Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit